{
    "organizations": [],
    "uuid": "ed227d7a7afa64118697318f3ba9411be6687e01",
    "author": "",
    "url": "https://www.reuters.com/article/brief-pulmatrix-announces-acceptance-of/brief-pulmatrix-announces-acceptance-of-a-clinical-trial-application-in-europe-for-pulmazole-idUSASB0C1QA",
    "ord_in_thread": 0,
    "title": "BRIEF-Pulmatrix Announces Acceptance Of A Clinical Trial Application In Europe For Pulmazole",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 22, 2018 / 6:00 PM / Updated 4 minutes ago BRIEF-Pulmatrix Announces Acceptance Of A Clinical Trial Application In Europe For Pulmazole Reuters Staff 1 Min Read \nJan 22 (Reuters) - Pulmatrix Inc: \n* PULMATRIX ANNOUNCES ACCEPTANCE OF A CLINICAL TRIAL APPLICATION IN EUROPE FOR PULMAZOLE - AN INHALED DRY-POWDER ISPERSEâ„¢ FORMULATION OF ITRACONAZOLE \n* PULMATRIX INC - EXPECTS THAT TOP LINE RESULTS FOR PUR1900 STUDY WILL BE AVAILABLE IN MID-2018 Source text for Eikon: Further company coverage:",
    "published": "2018-01-22T19:59:00.000+02:00",
    "crawled": "2018-01-22T20:12:46.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "acceptance",
        "clinical",
        "trial",
        "application",
        "europe",
        "pulmazole",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "pulmatrix",
        "inc",
        "pulmatrix",
        "announces",
        "acceptance",
        "clinical",
        "trial",
        "application",
        "europe",
        "pulmazole",
        "inhaled",
        "formulation",
        "itraconazole",
        "pulmatrix",
        "inc",
        "expects",
        "top",
        "line",
        "result",
        "pur1900",
        "study",
        "available",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}